USP7 inhibitors, downregulating CCDC6, sensitize lung neuroendocrine cancer cells to PARP-inhibitor drugs.
Sign Up to like & getrecommendations! Published in 2017 at "Lung cancer"
DOI: 10.1016/j.lungcan.2016.06.015
Abstract: OBJECTIVES CCDC6 gene product is a tumor-suppressor pro-apoptotic protein, substrate of ATM, involved in DNA damage response and repair. Altered levels of CCDC6 expression are dependent on post-translational modifications, being the de-ubiquitinating enzyme USP7 responsible… read more here.
Keywords: neuroendocrine cancer; cells parp; cancer cells; cancer ... See more keywords
Durable response to low-dose pralsetinib in a renal insufficient patient with NSCLC harboring concurrent CCDC6-RET, LINCO1264-RET, and SEMA5A-RET fusions: A case report
Sign Up to like & getrecommendations! Published in 2022 at "Medicine"
DOI: 10.1097/md.0000000000031480
Abstract: Introduction: RET-rearranged fusions have been considered as oncogenic drivers in 1% to 2% of non-small cell lung cancers (NSCLC). ARROW study has demonstrated a new selective RET tyrosine kinase inhibitors (TKIs) shows remarkable and durable… read more here.
Keywords: ccdc6; ret; patient; case ... See more keywords
High expression of CCDC6 in relation to unfavorable outcome and immune cells infiltration in hepatobiliary carcinoma
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Cancer"
DOI: 10.7150/jca.76050
Abstract: Background: The diagnosis of hepatobiliary carcinoma includes both hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA), the first and the second most common hepatobiliary malignancies, respectively. CCDC6 (coiled-coil domain-containing protein 6) is a protein that interacts with… read more here.
Keywords: ccdc6; expression; immune cells; hepatobiliary carcinoma ... See more keywords